Meningococcal conjugate vaccines

Bibliography

• Epidemics of meningococcal disease. African meningitis belt, 2001. Wkly Epidemic] Rec. (2001) 76:282–288.
   PubMedGoogle Scholar
• ROSENSTEIN NE, PERKINS BA, STEPHENS DS, POPOVIC T, HUGHES JM: Meningococcal disease.N. Eng] Med. (2001) 344:1378-1388.
   Google Scholar
• ••This paper is an important andcomprehensive review of meningococcal disease epidemiology, clinical manifestations and prevention.
   Google Scholar
• LINGAPPA JR, AL-RABEAH AM, HAJJEH R et al.: Serogroup W-135 meningococcal disease during the Hajj, 2000. Enter& Infect. Dis. (2003) 9:665–671.
   PubMed Web of Science ®Google Scholar
• ARTENSTEIN MS, GOLD R, ZIMMERLY JG,WYLE FA, SCHNEIDER H, HARKINS C: Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl. Med. (1970) 282:417–420.
   PubMed Web of Science ®Google Scholar
• ••This reference is an important example ofan early vaccine trial and the efficacy of the serogroup C polysaccharide vaccine.
   Google Scholar
• GOLD R, LEPOW ML, GOLDSCHNEIDER I, GOTSCHLICH EC: Immune response of human infants of polysaccharide vaccines of group A, C Neisseria meningitidis. .1. Infect. Dis. (1977) 136(Suppl.):S31–S35.
   Google Scholar
• •Discusses the science behind development of the meningococcal polysaccharide vaccines.
   Google Scholar
• GOLDSCHNEIDER I, GOTSCHLICH EC, ARTENSTEIN MS: Human immunity to the meningococcus. I. The role of humoral antibodies. I Exp. Med. (1969) 129:1307–1326.
   PubMed Web of Science ®Google Scholar
• •Discusses the science behind development of the meningococcal polysaccharide vaccines.
   Google Scholar
• GOTSCHLICH EC, GOLDSCHNEIDER I, ARTENSTEIN MS: Human immunity to the meningococcus. IV Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. .1 Exp. Med. (1969) 129:1367–1384.
   Google Scholar
• •Discusses the science behind development of the meningococcal polysaccharide vaccines.
   Google Scholar
• GOTSCHLICH EC, GOLDSCHNEIDER I, ARTENSTEIN MS: Human immunity to the meningococcus. V The effect of immunization with meningococcal group C polysaccharide on the carrier state. .1 Exp. Med. (1969) 129:1385–1395.
   Google Scholar
• •Discusses the science behind development of the meningococcal polysaccharide vaccines.
   Google Scholar
• RICHMOND P, KACZMARSKI E, BORROW R et al.: Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. j Infect. Dis. (2000) 181:761–764.
   PubMed Web of Science ®Google Scholar
• ZHANG Q, LAKSHMAN R, BURKINSHAW R et al.: Primary and booster mucosal immune responses to meningococcal group A, C conjugate and polysaccharide vaccines administered to university students in the United Kingdom. Infect. Inman. (2001) 69:4337–4341.
   PubMed Web of Science ®Google Scholar
• MACDONALD NE, HALPERIN SA, LAW BJ, DANZIG LE, GRANOFF DM: Can meningococcal C conjugate vaccine overcome immune hyporesponsiveness induced by previous administration of plain polysaccharide vaccine? JAMA (2000) 283: 1826-1827.
   Google Scholar
• ROSENSTEIN NE, PERKINS BA, STEPHENS DS et al: The changing epidemiology of meningococcal disease in the United States, 1992-1996.1 Infect. Dis. (1999) 180:1894–901.
   PubMed Web of Science ®Google Scholar
• GREENWOOD BM, WALI SS: Control of meningococcal infection in the African meningitis belt by selective vaccination. Lancet (1980) 1:729–732.
   PubMed Web of Science ®Google Scholar
• ZANGWILL KM, SCHUCHAT A, RIEDO FX et al.: School-based clusters of meningococcal disease in the United States. Descriptive epidemiology and a case-control analysis. JAMA (1997) 277:389–395.
   Google Scholar
• HOUCK P, PATNODE M, ATWOOD R, POWELL K: Epidemiologic characteristics of an outbreak of serogroup C meningococcal disease and the public health response. Public Health Rep. (1995) 110:343–349.
   PubMedGoogle Scholar
• HUME SE: Mass voluntary immunization campaigns for meningococcal disease in Canada: media hysteria. JAMA (1992) 267:1833-1834, 1837–1838.
   Google Scholar
• Outbreaks of group B meningococcal disease-Florida, 1995 and 1997. MMWR Morb. Mortal. Wkly Rep. (1998) 47:833–837.
   Google Scholar
• JONES GR, CHRISTODOULIDES M, BROOKS JL, MILLER AR, CARTWRIGHT KA, HECKELS JE: Dynamics of carriage of Neisseria meningitidis in a group of military recruits: subtype stability and specificity of the immune response following colonization. J. Infect. Dis. (1998) 178:451–459.
   PubMed Web of Science ®Google Scholar
• •This reference is an important description of the dynamics of nasopharyngeal colonisation.
   Google Scholar
• RIORDAN T, CARTWRIGHT K, ANDREWS N et al.: Acquisition and carriage of meningococci in marine commando recruits. Epidemiol. Infect. (1998) 121:495–505.
   PubMedGoogle Scholar
• DE WALS P, GILQUIN C, DE MAEYER S et al.: Longitudinal study of asymptomatic meningococcal carriage in two Belgian populations of schoolchildren. J. Infect. (1983) 6:147–156.
   Google Scholar
• KAHLER CM, STEPHENS DS: Genetic basis for biosynthesis, structure, and function of meningococcal lipooligosaccharide (endotoxin). Crit. Rev. Microbiol. (1998) 24:281–334.
   PubMed Web of Science ®Google Scholar
• STEPHENS DS, ZIMMER SM: Pathogenesis, Therapy, and Prevention of Meningococcal Sepsis. Carr: Infect. Dis. Rep. (2002) 4:377–386.
   PubMedGoogle Scholar
• SWARTLEY JS, MARFIN AA, EDUPUGANTI S et at: Capsule switching of Neisseria meningitidis. Proc. Natl. Acad. Sci. USA (1997) 94:271–276.
   PubMed Web of Science ®Google Scholar
• Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. (2000) 49:1–10.
   Google Scholar
• HARRIS SL, KING WJ, FERRIS W, GRANOFF DM: Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine. Infect. Immun. (2003) 71:275–286.
   PubMedGoogle Scholar
• ROSENSTEIN NE, FISCHER M, TAPPERO JW: Meningococcal vaccines. Infect. Dis. Clin. North Am. (2001) 15:155–169.
   PubMed Web of Science ®Google Scholar
• ARTENSTEIN MS, BRANDT BL: Immunologic hyporesponsiveness in man to group C meningococcal polysaccharide. Immunol. (1975) 115:5–7.
   Google Scholar
• GRANOFF DM, GUPTA RK, BELSHE RB, ANDERSON EL: Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. Infect. Dis. (1998) 178:870–874.
   Google Scholar
• GOLD R, LEPOW ML, GOLDSCHNEIDER I, DRAPER TF, GOTSHLICH EC: Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J. Infect. Dis. (1979) 140:690–697.
   PubMed Web of Science ®Google Scholar
• LEPOW ML, GOLDSCHNEIDER I, GOLD R, RANDOLPH M, GOTSCHLICH EC: Persistence of antibody following immunization of children with groups A, C meningococcal polysaccharide vaccines. Pediatrics (1977) 60:673–680.
   PubMed Web of Science ®Google Scholar
• ZANGWILL KM, STOUT RW, CARLONE GM et al.: Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel. Infect. Dis. (1994) 169:847–852.
   Google Scholar
• HASSAN-KING MK, WALL RA, GREENWOOD BM: Meningococcal carriage, meningococcal disease and vaccination. Infect. (1988) 16:55–59.
   Google Scholar
• STROFFOLINI T, ANGELINI L, GALANTI I, OCCHIONERO M, CONGIU ME, MASTRANTONIO P: The effect of meningococcal group A, C polysaccharide vaccine on nasopharyngeal carrier state. Microbiologica (1990) 13:225–229.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ S, ARREAZA L, SANTIAGO I et al.: Impact of meningococcal vaccination with combined serogroups A, C polysaccharide vaccines on carriage of Neisseria meningitidis C. J. Med. Microbiol. (2003) 52:75–77.
   PubMed Web of Science ®Google Scholar
• Meningococcal vaccine and college students: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly. Rep. (2000) 49:11–20.
   PubMedGoogle Scholar
• ••These are the guidelines for currentmeningococcal vaccination in the US.
   Google Scholar
• MEMISH ZA: Meningococcal disease and travel. Clin. Infect. Dis. (2002) 34:84–90.
   PubMedGoogle Scholar
• ROSENSTEIN N, LEVINE 0, TAYLOR JP et al.: Efficacy of meningococcal vaccine and barriers to vaccination. JAMA (1998) 279:435–439.
   Google Scholar
• LEAKE JA, KONE ML, YADA AA, BARRY LF, TRAORE G et al.: Early detection and response to meningococcal disease epidemics in sub-Saharan Africa: appraisal of the WHO strategy. Bull. World Health Organ. (2002) 80:342–349.
   PubMedGoogle Scholar
• WOODS CW, ARMSTRONG G, SACKEY SO et al.: Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa. Lancet (2000) 355:30–33.
   PubMed Web of Science ®Google Scholar
• MACLENNAN JM, SHACKLEY F, HEATH PT, DEEKS JJ et al.: Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial. JAMA (2000) 283:2795–801.
   PubMed Web of Science ®Google Scholar
• HEATH PT: Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr. Infect. Dis. J. (1998) 17:S117–22.
   PubMed Web of Science ®Google Scholar
• KLUGMAN KP, MADHI SA, HUEBNER RE, KOHBERGER R, MBELLE N, PIERCE N: A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl. J. Med. (2003) 349:1341–1348.
   PubMed Web of Science ®Google Scholar
• WHITNEY CG, FARLEY MM, HADLER J et al, and the ACTIVE BACTERIAL CORE SURVEILLANCE OF THE EMERGING INFECTIONS PROGRAM NETWORK: Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl. J. Med. (2003) 348:1737–1746.
   PubMed Web of Science ®Google Scholar
• ADA G: Vaccines and Vaccination. N. Engl. J. Med. (2001) 345:1042–1053.
   PubMedGoogle Scholar
• PELTOLA H, KILPI T, ANTTILA M: Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet (1992) 340:592–594.
   PubMed Web of Science ®Google Scholar
• KLUGMAN KP: Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance. Lancet Infect. Dis. (2001) 1:85–91.
   PubMedGoogle Scholar
• ZHANG Q, CHOO S, EVERARD J, JENNINGS R, FINN A: Mucosal immune responses to meningococcal group C conjugate and group A, C polysaccharide vaccines in adolescents. Infect. Inman. (2000) 68:2692–2697.
   PubMed Web of Science ®Google Scholar
• ZHANG Q, PETTITT E, BURKINSHAW R, RACE G, SHAW L, FINN A: Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants. Pediatr. Infect. Dis. J. (2002) 21:209–213.
   PubMed Web of Science ®Google Scholar
• RAMSAY ME, ANDREWS N, KACZMARSKI EB, MILLER E: Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet (2001) 357:195–196.
   PubMed Web of Science ®Google Scholar
• ••This reference demonstrates the earlyefficacy of the conjugate serogroup C vaccine in the UK.
   Google Scholar
• TROTTER CL, RAMSAY ME, KACZMARSKI EB: Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun. Dis. Public Health (2002) 5:220–225.
   PubMedGoogle Scholar
• RICHMOND P, BORROW R, GOLDBLATT D et al.: Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. .1. Infect. Dis. (2001) 183:160–163.
   Google Scholar
• MCVERNON J, MACLENNAN J, POLLARD AJ et al.: Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years. Pediatr. Infect. Dis. J. (2003) 22:659–661.
   PubMed Web of Science ®Google Scholar
• MCVERNON J, MACLENNAN J, BUTTERY J, OSTER P, DANZIG L, MOXON ER: Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children. Pediatr. Infect. Dis. 1 (2002) 21:747–753.
   PubMed Web of Science ®Google Scholar
• MACDONALD NE, HALPERIN SA, LAW BJ, FORREST B, DANZIG LE, GRANOFF DM: Induction of immunologic memory by conjugated versus plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA (1998) 280:1685–1689.
   PubMed Web of Science ®Google Scholar
• ••This reference highlights the improvedimmunogenicity of the conjugate vaccine compared to the polysaccharide vaccine in toddlers.
   Google Scholar
• BORROW R, GOLDBLATT D, FINN A et al.: Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C- tetanus toxoid conjugate vaccine in infants in the United kingdom. Infect. Immun. (2003) 71:5549–5555.
   PubMed Web of Science ®Google Scholar
• BORROW R, FOX AJ, RICHMOND PC et al: Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine. Epidemiol. Infect. (2000) 124:427–432.
   PubMed Web of Science ®Google Scholar
• BALMER P, BORROW R, MILLER E: Impact of meningococcal C conjugate vaccine in the UK. J. Med. Microbiol. (2002) 51:717–722.
   PubMed Web of Science ®Google Scholar
• MAIDEN MC, STUART JM: Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet (2002) 359: 1829-1831.
   Google Scholar
• RAMSAY ME, ANDREWS NJ, TROTTER CL, KACZMARSKI EB, MILLER E: Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. Br. Med. J. (2003) 326:365–366.
   PubMed Web of Science ®Google Scholar
• DEEKS S, KERTESZ D, RYAN A, JOHNSON W, ASHTON F: Surveillance of invasive meningococcal disease in Canada, 1995-1996. Can. Commun. Dis. Rep. (1997) 23:121–125.
   PubMedGoogle Scholar
• BRICKS LF: Critical analysis of old and new vaccines against N. meningitidis serogroup C, considering the meningococcal disease epidemiology in Brazil. Rev. Hosp. Clin. Fac. Med. Sao Paulo (2003) 58:231–240.
   Google Scholar
• Supplementary statement on conjugate meningococcal vaccines. Can. Commun. Dis. Rep. CCDR (2003) 29:10–12.
   Google Scholar
• PEREZ-TRALLERO E, VICENTE D, MONTES M, CISTERNA R: Positive effect of meningococcal C vaccination on serogroup replacement in Neisseria meningitidis. Lancet (2002) 360:953.
   PubMed Web of Science ®Google Scholar
• CAMPAGNE G, GARBA A, FABRE P et al.: Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr. Infect. Dis. J. (2000) 19:144–150.
   PubMed Web of Science ®Google Scholar
• LEACH A, TWUMASI PA, KUMAH S et al.: Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J. Infect. Dis. (1997) 175:200–204.
   PubMed Web of Science ®Google Scholar
• TWUMASI PA Jr, KUMAH S, LEACH Aet al.: A trial of a group A plus group Cmeningococcal polysaccharide-protein conjugate vaccine in African infants. J. Infect. Dis. (1995) 171:632–638.
   Google Scholar
• BERRY DS, LYNN F, LEE CH, FRASCH CE, BASH MC: Effect of 0-acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses. Infect. Immun. (2002) 70:3707–3713.
   PubMed Web of Science ®Google Scholar
• JIN Z, CHU C, ROBBINS JB, SCHNEERSON R: Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice. Infect. Immun. (2003) 71:5115–5120.
   PubMedGoogle Scholar
• KEYSERLING HL, PAPA T, BYBEL M: A comparative trial of the safety and immunogenicity of an experimental tetravalent meningococcal (A, C, Y, W-135) diphtheria conjugate vaccine versus a licensed meningococcal (A, C, Y, and W-135) polysaccharide vaccine in healthy adolescents. 43-d Interscience Conference on Antimicrobial Agents and Cliemotberapeutics (2003) G–2051.
   Google Scholar
• GRIFFISS JM, YAMASAKI R, ESTABROOK M, KIM JJ: Meningococcal molecular mimicry and the search for an ideal vaccine. Trans. R. Soc. Bop. Med. Hyg. (1991) 85\(Suppl. 1):32–36.
   Google Scholar
• PON RA, LUSSIER M, YANG QL, JENNINGS HJ: N-Propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis. Exp. Med. (1997) 185:1929–1938.
   PubMed Web of Science ®Google Scholar
• JENNINGS HJ, GAMIAN A, ASHTON FE: N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis. I Exp. Med. (1987) 165:1207–1211.
   PubMed Web of Science ®Google Scholar
• JENNINGS HJ, ROY R, GAMIAN A: Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J. Immunol (1986) 137:1708–1713.
   PubMed Web of Science ®Google Scholar
• BJUNE G, HOIBY EA, GRONNESBY JKet al: Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet (1991) 338:1093–1096.
   PubMed Web of Science ®Google Scholar
• BJUNE G, GRONNESBYJK, HOIBY EA,CLOSS 0, NOKLEBY H: Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B 862 meningococcal disease in Norway. NIPH Ann. (1991) 14:125-130; Discussion 130–132.
   Google Scholar
• TAPPERO JW, LAGOS R, BALLESTEROS AM et al.: Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA (1999) 281:1520–1527.
   PubMed Web of Science ®Google Scholar
• BAKER MG, MARTIN DR, KIEFT CE, LENNON D: A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. J. Paediatr. Child Health (2001) 37:S13–S19.
   Google Scholar
• KLEIJN E, DE VAN EIJNDHOVEN L, VERMONT C et al.: Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine. Vaccine (2001) 20:352–358.
   Google Scholar
• DE KLEIJN ED, DE GROOT R, LAFEBER AB et al.: Prevention of meningococcal serogroup B infections in children: a protein-based vaccine induces immunologic memory. J. Infect. Dis. (2001) 184:98–102.
   PubMedGoogle Scholar
• DE KLEIJN ED, DE GROOT R, LABADIE J et al.: Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine (2000) 18:1456–1466.
   PubMed Web of Science ®Google Scholar
• VERMONT CL, VAN DIJKEN HH, KUIPERS Al et al.: Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine. Infect. Immun. (2003) 71:1650–1655.
   PubMed Web of Science ®Google Scholar
• TONDELLA ML, POPOVIC T, ROSENSTEIN NE et al.: Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. Clin. Microbial (2000) 38:3323–3328.
   Google Scholar
• GASPAR M, LEITE F, BRUMANA L, FELIX B, STELLA AA: Epidemiology of meningococcal meningitis in Angola, 1994-2000. Epidemial Infect. (2001) 127:421–424.
   PubMedGoogle Scholar
• TAHA MK, PARENT DU, CHATELET I et al.: Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. Clin. Microbial (2002) 40:1083–1084.
   PubMed Web of Science ®Google Scholar
• GAGNEUX SP, HODGSON A, SMITH TA et al.: Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J. Infect. Dis. (2002) 185:618–626.
   PubMed Web of Science ®Google Scholar
• From the Centers for Disease Control and Prevention. Serogroup Y meningococcal disease-Illinois, Connecticut, and selected areas, United States, 1989-1996. JA/VIA (1996) 276: 1866-1867.
   Google Scholar
• MORLEY SL, COLE MJ, ISON CA et al.: Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants. Pediatr. Infect. Dis. J. (2001) 20:1054–1061.
   PubMed Web of Science ®Google Scholar
• BAKKE H, LIE K, HAUGEN IL et al: Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance. Infect. Immun. (2001) 69:5010–5015.
   PubMed Web of Science ®Google Scholar
• DEVI SJ, ZOLLINGER WD, SNOY PJ et al.: Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys. Infect. Immun. (1997) 65:1045–1052.
   PubMed Web of Science ®Google Scholar
• ZOLLINGER WD, MORAN EE, DEVI SJ, FRASCH CE: Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Infect. Litman. (1997) 65:1053–1060.
   Google Scholar
• http://www.whoint/csr/disease/meningococc al/icg/en/ International Coordinating Group (ICG) on Vaccine Provision for Epidemic Meningitis Control. February (2004).
   Google Scholar
• http://www.meningvax.org/WHO and Path Meningitis Vaccine Project, 2003–2004. February 1(2004).
   Google Scholar
• http://www.who.int/mediacentre/releases/ 192003/pr9/en/Partnership moves in record time to providevaccine against meningitis as epidemic emerges in Africa, 2003. February (2004).
   Google Scholar
• http://www.aventis.com/main/page.asp?pagei d=3489520031221234224&lang=en Aventis submits application for FDA-approval of Menactra'", the first candidate quadrivalent conjugate meningococcal vaccine, 2003. February (2004).
   Google Scholar